To solidify this and be able to incorporate estrogen therapy in the preventive management of dementia in women, we need larger-scale studies specifically targeting women with risk factors for cognitive decline, like women with a family history of dementia or early-onset dementia, APOE4 carriers, women with early-onset menopause, such as those with premature ovarian insufficiency, and women with cerebrovascular disease. This evidence concerns the gene APOE and cerebrovascular disorder.